AI assistant
ARS Pharmaceuticals, Inc. — Director's Dealing 2022
Sep 8, 2022
32159_dirs_2022-09-08_27b4584c-ea60-4e49-9698-069791c7a7be.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2022-09-02
Reporting Person: Pepe Jeffrey C. (Interim CEO and GC)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 52323 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock option (right to buy) | $1.68 | 2029-09-10 | Common Stock (35407) | Direct | |
| Stock option (right to buy) | $1.27 | 2030-04-28 | Common Stock (22401) | Direct | |
| Stock option (right to buy) | $1.27 | 2030-04-28 | Common Stock (17619) | Direct | |
| Stock option (right to buy) | $1.27 | 2030-04-28 | Common Stock (18268) | Direct | |
| Stock option (right to buy) | $6.65 | 2030-09-30 | Common Stock (26932) | Direct | |
| Stock option (right to buy) | $21.00 | 2030-12-02 | Common Stock (102039) | Direct | |
| Stock option (right to buy) | $4.85 | 2032-01-31 | Common Stock (45000) | Direct | |
| Stock option (right to buy) | $4.85 | 2032-01-31 | Common Stock (28500) | Direct | |
| Stock option (right to buy) | $3.15 | 2032-05-01 | Common Stock (79261) | Direct |
Footnotes
F1: 25% of the shares subject to the option vested on August 19, 2020, and the remaining shares will vest monthly thereafter over three years.
F2: 25% of the shares subject to the option vested on March 4, 2021, and the remaining shares will vest monthly thereafter over three years.
F3: 25% of the shares subject to the option vested on July 1, 2021, and the remaining shares will vest monthly thereafter over three years.
F4: The shares subject to the option will vest in equal monthly installments over the 48 months beginning on October 18, 2020.
F5: The shares subject to the option will vest in equal monthly installments over the 48 months beginning on October 22, 2020.
F6: The shares subject to the option will vest in equal monthly installments over the 48 months beginning on January 3, 2021.
F7: The shares subject to the option will vest in equal monthly installments over the 48 months beginning on March 1, 2022.
F8: 25% of the shares subject to the option will vest on February 1, 2023, and the remaining shares will vest monthly thereafter over three years.
F9: The shares subject to the option will vest on May 2, 2023.